Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic ...

Regeneron Pharmaceuticals announced that the ... Odronextamab is already approved in the EU under the name Ordspono™ for similar indications. The ongoing clinical development program for ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

Learn more about whether AbbVie Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Regeneron Pharmaceuticals ... Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy.

Regeneron Pharmaceuticals is taking another ... under the brand name Ordspono for r/r FL and diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...